WillItSurvive
Medical technology and health companies · United States

Veracyte

veracyte.com ↗

Veracyte makes genomic tests that guide cancer treatment decisions for thyroid and prostate patients.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from July 30, 2026 · Every call on the record Checkpoint: Q2 2026 earnings plus OPTIMA and ENZIMET trial readouts
The call

Veracyte's thyroid and prostate tests sit behind Medicare and guideline walls that took a decade to build, while Natera and Guardant race ahead in the newer MRD monitoring market next door.

Veracyte runs a genetics lab that analyzes blood and tissue samples to help doctors catch cancer early and pick the right treatment. The company's core tests for thyroid and prostate cancer are protected because they took decades to prove they work, they are covered by Medicare and medical guidelines, and competitors like Natera and Guardant would need to repeat all that testing and paperwork to copy them. The big risk is whether Veracyte can catch up in a newer test type called MRD (minimal-residual-disease), where Natera and Guardant already have better insurance coverage and more doctors using them.

Why
01
AI pressure: None apparent. AI models can't replace Medicare-covered, NCCN-listed tests without their own trial data and payer approval, which takes years. Could AI do the core job? Unlikely.
02
Bigger players: Natera, Guardant Health. Natera and Guardant lead in MRD liquid biopsy adoption and payer coverage, pulling ahead in the newer cancer monitoring market. Could a giant copy it? No, they are blocked.
03
What protects it. Medicare coverage and NCCN guideline inclusion for Afirma and Decipher took years to win and lock out fast followers.
What would change this call
Natera or Guardant win NCCN guideline inclusion for a prostate MRD test overlapping Decipher's use case. Would show the MRD threat moving from adjacency into Veracyte's protected core.
Medicare LCD reversal or reduction affecting Afirma or Decipher reimbursement. Would show erosion of the regulatory/reimbursement moat protecting core revenue.
TrueMRD adoption rate and Medicare bladder coverage uptake after May 2026 start. Would show whether Veracyte can close the gap with Natera/Guardant in MRD.
Key numbers
  • FY2025 revenue $517.1M, up 16% YoY (2025-12-31)
  • Adjusted EBITDA margin 27.6%, beat 25% target early (2025-12-31)
  • Prostate cancer test share around 65% (2024-12-31)
Named risks
  • Natera or Guardant securing NCCN guideline inclusion for prostate MRD overlapping Decipher's use case. Severity: high
  • Medicare LCD reversal on Afirma or Decipher reimbursement. Severity: high
  • Stock has risen 120% with new bets like Prosigna and TrueMRD unproven and excluded from guidance. Severity: medium
  • Ongoing employment discrimination lawsuit (Ligon v. Veracyte, filed 2026-07-09). Severity: low
  • Headcount reduction of 8.4% in 2025 alongside restructuring of French subsidiary. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Nateragaining onDescribed as ahead in MRD payer coverage and clinical adoption vs Veracyte's TrueMRD, as of 2026-03
Guardant Healthgaining onLeads in liquid biopsy/MRD payer coverage while Veracyte's TrueMRD is a 2024 catch-up bet
LabcorpcontestingLarge-scale incumbent that could expand into genomic oncology testing but has not shipped a competing NCCN-included classifier as of 2026-07
Quest DiagnosticscontestingDiversified diagnostics giant adjacent to Veracyte's space, no core-test overlap reported as of 2026-07
Exact SciencescontestingVendor-claimed dominant oncology franchise with strong hospital access, cited 2026-03-08
Questions people ask
Is Veracyte profitable in 2025?
Yes. Veracyte reported FY2025 net income of $66.35 million, up sharply from $24.14 million in 2024, on revenue of $517.1 million (up 16% year over year), with adjusted EBITDA margin of 27.6% as of December 31, 2025.
Could AI replace Veracyte's diagnostic tests?
Unlikely soon. Veracyte's classifiers already use machine learning, but its moat is Medicare coverage, NCCN guideline inclusion, and proprietary databases like Decipher GRID (100,000+ prostate profiles as of Feb 2023), which require years of clinical evidence an AI model cannot replicate overnight.
Who is Veracyte's biggest competitor?
In its core thyroid and prostate tests, Veracyte holds roughly 65% share (vendor-estimated, late 2024) with no dominant challenger. In the adjacent MRD/liquid biopsy space, Natera and Guardant Health are described as ahead in payer coverage and clinical adoption as of 2026.
Is Veracyte laying off employees?
Headcount fell from 824 to 755 employees between end of 2024 and end of 2025, an 8.4% decline, even as revenue grew 16%, reflecting restructuring including the liquidation of French subsidiary Veracyte SAS in 2025-2026.
Is Veracyte stock safe to invest in right now?
Veracyte's stock has been highly volatile, ranging from a 52-week low of $22.92 to trading near $58.20 on July 22, 2026, with a reported 120% rally by June 27, 2026. Fundamentals are strong, but the run-up and unproven new bets like MRD add risk.
What does Veracyte do?
Veracyte is a Nasdaq-listed (VCYT) genomic diagnostics company based in South San Francisco that develops molecular tests for thyroid (Afirma), prostate and bladder (Decipher), lung (Percepta), and breast cancer (Prosigna), generating $517.1 million in FY2025 revenue.
Timeline
  • 2026-07-09Employment discrimination lawsuit Ligon v. Veracyte filed
  • 2026-06Prosigna breast cancer test launched commercially in US as LDT
  • 2026-05Medicare coverage secured for TrueMRD bladder cancer monitoring test
  • 2026-05OPTIMA trial results for Prosigna presented at ASCO 2026
  • 2026-03-31Q1 2026 revenue reported at $139.1 million, up 21% YoY
  • 2026-02-25FY2025 results: $517.1M revenue, $66.35M net income, 27.6% EBITDA margin
  • 2025-05Veracyte files patent infringement suit against Sonic Healthcare USA and CPL
  • 2024-02C2i Genomics acquisition completed for MRD capabilities
  • 2023-02-13Decipher GRID database reported to exceed 100,000 prostate cancer profiles
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources